PE20121437A1 - Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes - Google Patents
Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetesInfo
- Publication number
- PE20121437A1 PE20121437A1 PE2012000492A PE2012000492A PE20121437A1 PE 20121437 A1 PE20121437 A1 PE 20121437A1 PE 2012000492 A PE2012000492 A PE 2012000492A PE 2012000492 A PE2012000492 A PE 2012000492A PE 20121437 A1 PE20121437 A1 PE 20121437A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- diabetes
- treatment
- phenyl
- pharmaceutical use
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 2
- -1 SPIROPIPERIDINE COMPOUND Chemical class 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000006519 CCH3 Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE ESPIROPIPERIDINA DE FORMULA (I) DONDE: R1 ES H, F Y CLORO; R2 ES H, ALQUILO C1-3, CF3, OCH3, F Y CLORO; R3 ES H Y ALQUILO C1-3; R4 Y R4a SON INDEPENDIENTEMENTE H, OCH3, ALQUILO C1-3, CF3 Y FLUOR; R5 ES H O C?CCH3; X ES CH(R3)CH2-, -C(R3)=CH-, -N(R7)CH2- Y -C(O)CH2-; R7 ES H, ALQUILO C1-3 Y FENILO; SON COMPUESTOS PREFERIDOS: ACIDO (3S)-3-(4-{[4-(1'H-ESPIRO[INDEN-1,4'-PIPERIDIN]-1'-ILMETIL)BENCIL]OXI}FENIL)HEX-4-INOICO; ACIDO (3S)-3-[4-({4-[(1-METIL-1,2,-DIHIDRO-1'H-ESPIRO[INDOL-3,4'-PIPERIDIN]-1'-IL)METIL]BENCIL}OXI)FENIL]HEX-4-INOICO; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES MODULADOR DEL RECEPTOR 40 ACOPLADO A LA PROTEINA G (RPG-40), SIENDO UTIL EN EL TRATAMIENTO DE LA DIABETES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25183909P | 2009-10-15 | 2009-10-15 | |
| US30333410P | 2010-02-11 | 2010-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121437A1 true PE20121437A1 (es) | 2012-10-26 |
Family
ID=43719548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000492A PE20121437A1 (es) | 2009-10-15 | 2010-10-11 | Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8383642B2 (es) |
| EP (1) | EP2488500A1 (es) |
| JP (1) | JP2013508279A (es) |
| KR (1) | KR20120051777A (es) |
| CN (1) | CN102574807A (es) |
| AR (1) | AR078522A1 (es) |
| AU (1) | AU2010307094A1 (es) |
| BR (1) | BR112012008889A2 (es) |
| CA (1) | CA2777775A1 (es) |
| CL (1) | CL2012000921A1 (es) |
| CO (1) | CO6531458A2 (es) |
| CR (1) | CR20120177A (es) |
| DO (1) | DOP2012000105A (es) |
| EA (1) | EA201270560A1 (es) |
| EC (1) | ECSP12011799A (es) |
| IL (1) | IL218344A0 (es) |
| MA (1) | MA33662B1 (es) |
| MX (1) | MX2012004420A (es) |
| NZ (1) | NZ598972A (es) |
| PE (1) | PE20121437A1 (es) |
| PH (1) | PH12012500705A1 (es) |
| TN (1) | TN2012000152A1 (es) |
| TW (1) | TW201124415A (es) |
| WO (1) | WO2011046851A1 (es) |
| ZA (1) | ZA201202560B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP3280A (en) | 2009-03-23 | 2015-05-31 | Glenmark Pharmaceuticals Sa | Fused pyrimidine-dione derivatives as TRPA1 modulators |
| PT2411395E (pt) | 2009-03-23 | 2013-06-06 | Glenmark Pharmaceuticals Sa | Derivados de furopirimidinadiona como moduladores de trpa1 |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| NZ601408A (en) | 2009-12-25 | 2013-12-20 | Mochida Pharm Co Ltd | Novel 3-hydroxy-5-arylisothiazole derivative |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| PL2683251T3 (pl) | 2011-03-11 | 2021-12-13 | Intercontinental Great Brands Llc | Sposób wytwarzania wielowarstwowych wyrobów cukierniczych |
| BR112013027883A2 (pt) | 2011-04-27 | 2017-08-08 | Mochida Pharm Co Ltd | novo derivado de 1-óxido de 3-hidroxiisotiazol |
| AU2012248627A1 (en) | 2011-04-28 | 2013-11-14 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| TWI537262B (zh) | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
| WO2013139341A1 (en) * | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
| WO2013185766A1 (en) * | 2012-06-15 | 2013-12-19 | Syddansk Universitet | Gpr120 receptor modulators |
| WO2014078610A1 (en) | 2012-11-16 | 2014-05-22 | Bristol-Myers Squibb Company | Dihydropyrazole gpr40 modulators |
| KR101569522B1 (ko) * | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| IN2013MU03577A (es) * | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
| US20150351889A1 (en) | 2014-06-05 | 2015-12-10 | Vivex Biomedical Inc. | Dynamic Biometric Mesh |
| WO2016060517A2 (ko) * | 2014-10-17 | 2016-04-21 | 현대약품 주식회사 | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
| US11964938B2 (en) | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1385514E (pt) * | 2001-04-18 | 2009-02-04 | Euro Celtique Sa | Compostos espiroindeno e espiroindano |
| JP3856815B2 (ja) * | 2003-04-04 | 2006-12-13 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体アゴニストとしてのアシル化スピロピペリジン誘導体 |
| US7504506B2 (en) * | 2003-11-04 | 2009-03-17 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| JP5299810B2 (ja) | 2004-02-27 | 2013-09-25 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
| JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| US8299296B2 (en) * | 2007-10-26 | 2012-10-30 | Japan Tobacco Inc. | Spiro compounds and pharmaceutical use thereof |
| ES2469824T3 (es) * | 2007-11-21 | 2014-06-20 | Janssen Pharmaceutica N.V. | Espiropiperidinas para su uso como inhibidores de la triptasa |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
-
2010
- 2010-10-04 AR ARP100103604A patent/AR078522A1/es not_active Application Discontinuation
- 2010-10-06 TW TW099134098A patent/TW201124415A/zh unknown
- 2010-10-11 MX MX2012004420A patent/MX2012004420A/es not_active Application Discontinuation
- 2010-10-11 CN CN2010800462763A patent/CN102574807A/zh active Pending
- 2010-10-11 EP EP10793349A patent/EP2488500A1/en not_active Withdrawn
- 2010-10-11 CA CA2777775A patent/CA2777775A1/en not_active Abandoned
- 2010-10-11 US US12/901,597 patent/US8383642B2/en not_active Expired - Fee Related
- 2010-10-11 KR KR1020127009501A patent/KR20120051777A/ko not_active Ceased
- 2010-10-11 BR BR112012008889A patent/BR112012008889A2/pt not_active IP Right Cessation
- 2010-10-11 JP JP2012534259A patent/JP2013508279A/ja not_active Withdrawn
- 2010-10-11 WO PCT/US2010/052126 patent/WO2011046851A1/en not_active Ceased
- 2010-10-11 EA EA201270560A patent/EA201270560A1/ru unknown
- 2010-10-11 PH PH1/2012/500705A patent/PH12012500705A1/en unknown
- 2010-10-11 AU AU2010307094A patent/AU2010307094A1/en not_active Abandoned
- 2010-10-11 PE PE2012000492A patent/PE20121437A1/es not_active Application Discontinuation
- 2010-10-11 NZ NZ598972A patent/NZ598972A/xx not_active IP Right Cessation
-
2012
- 2012-02-27 IL IL218344A patent/IL218344A0/en unknown
- 2012-04-02 TN TNP2012000152A patent/TN2012000152A1/en unknown
- 2012-04-09 MA MA34760A patent/MA33662B1/fr unknown
- 2012-04-10 ZA ZA2012/02560A patent/ZA201202560B/en unknown
- 2012-04-12 CR CR20120177A patent/CR20120177A/es not_active Application Discontinuation
- 2012-04-12 CL CL2012000921A patent/CL2012000921A1/es unknown
- 2012-04-13 EC ECSP12011799 patent/ECSP12011799A/es unknown
- 2012-04-13 DO DO2012000105A patent/DOP2012000105A/es unknown
- 2012-04-20 CO CO12065315A patent/CO6531458A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL218344A0 (en) | 2012-04-30 |
| EP2488500A1 (en) | 2012-08-22 |
| CR20120177A (es) | 2012-06-06 |
| JP2013508279A (ja) | 2013-03-07 |
| NZ598972A (en) | 2013-06-28 |
| ZA201202560B (en) | 2013-09-25 |
| AR078522A1 (es) | 2011-11-16 |
| ECSP12011799A (es) | 2012-07-31 |
| CL2012000921A1 (es) | 2012-09-14 |
| KR20120051777A (ko) | 2012-05-22 |
| AU2010307094A1 (en) | 2012-04-19 |
| WO2011046851A1 (en) | 2011-04-21 |
| MA33662B1 (fr) | 2012-10-01 |
| US8383642B2 (en) | 2013-02-26 |
| TN2012000152A1 (en) | 2013-12-12 |
| TW201124415A (en) | 2011-07-16 |
| CN102574807A (zh) | 2012-07-11 |
| DOP2012000105A (es) | 2013-01-31 |
| CA2777775A1 (en) | 2011-04-21 |
| PH12012500705A1 (en) | 2012-10-29 |
| CO6531458A2 (es) | 2012-09-28 |
| EA201270560A1 (ru) | 2012-09-28 |
| BR112012008889A2 (pt) | 2019-09-24 |
| US20110092531A1 (en) | 2011-04-21 |
| MX2012004420A (es) | 2012-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121437A1 (es) | Compuestos de espiropiperidina y uso farmaceutico de los mismos para el tratamiento de diabetes | |
| PE20121474A1 (es) | Nuevos compuestos de espiropiperidina | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| PE20121518A1 (es) | Bloqueantes de los canales de sodio dependientes de voltaje | |
| RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
| PE20110136A1 (es) | Compuestos organicos | |
| PE20140868A1 (es) | Antagonistas trpm8 y su uso en tratamientos | |
| PE20090815A1 (es) | Compuesto de amida | |
| PE20120261A1 (es) | Piperidina espiro pirrolidinona y piperidinonas sustitudos como moduladores de los receptores h3 | |
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| PE20080706A1 (es) | Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| PE20091014A1 (es) | Compuestos espiro y uso farmaceutico de los mismos | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| PE20090949A1 (es) | Compuesto heterociclico y composicion farmaceutica del mismo | |
| CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. | |
| PE20110329A1 (es) | Agonistas del receptor acoplado a la proteina g piperidinilo | |
| RU2008136756A (ru) | Гетеробициклические противовирусные соединения | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
| PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado | |
| JP2013538801A5 (es) | ||
| PE20141361A1 (es) | Compuesto heterociclico dihidroxi aromatico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |